Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
Stocks · News reference
Quantum BioPharma Featured in Men's Fitness Article on Unbuzzd Clinical Trial Results
Quantum BioPharma was featured in a Men's Fitness article discussing clinical trial results for its Unbuzzd wellness product.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial
Quantum BioPharma signed an agreement with Thermo Fisher to initiate a Phase 2 clinical trial for its multiple sclerosis therapy, Lucid-MS.
EXCLUSIVE: Quantum BioPharma Contracts With Thermo Fisher Scientific Clinical Research Business To Support Phase 2 Trial For Neuroprotective Therapy In Multiple Sclerosis; Financial Terms Not Disclosed
Quantum BioPharma’s Licensee Unbuzzd Wellness Announces Appointment Of Michael Zapolin As CEO
Quantum BioPharma Ltd. (NASDAQ:QNTM) (FRA: 0K91) ("Quantum BioPharma"), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind
Quantum BioPharma Says FDA Cleared IND Application For Lucid-MS In Multiple Sclerosis, Enabling Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial